Patents by Inventor Gerald Roth

Gerald Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070111981
    Abstract: The present invention relates to (hetero)aryl compounds of general formula I wherein the groups and radicals A, B, Q, W, X, Y, Z, R1, R2, R4a, R4b, R5a, R5b, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: October 25, 2006
    Publication date: May 17, 2007
    Inventors: Gerald Roth, Stephan Mueller, Thorsten Lehmann-Lintz, Dirk Stenkamp, Philipp Lustenberger, Joerg Kley, Klaus Rudolf, Armin Heckel, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20070088051
    Abstract: The invention relates to indolinone compounds of formula (I), wherein Y and R1 to R8 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
    Type: Application
    Filed: November 13, 2006
    Publication date: April 19, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Steffen Steurer, Ralph Brueckner, Bernd Krist, Bodo Betzemeier, Frank Hilberg, Armin Heckel, Gerald Roth, Joerg Kley, Thorsten Lehmann-Lintz
  • Patent number: 7166615
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Patent number: 7160901
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 9, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Publication number: 20070004757
    Abstract: The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R1 to R6 and X are as defined in Claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    Type: Application
    Filed: September 7, 2006
    Publication date: January 4, 2007
    Inventors: Gerald Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley, Frank Hilberg, Jacobus Van Meel, Ulrik Tontsch-Grunt
  • Publication number: 20060258681
    Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate of formula I and the use thereof as a pharmaceutical composition.
    Type: Application
    Filed: July 28, 2006
    Publication date: November 16, 2006
    Inventors: Gerald Roth, Guenter Linz, Peter Sieger, Werner Rall, Frank Hilberg, Thomas Bock
  • Publication number: 20060194813
    Abstract: The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R1 to R6 and X are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 31, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Armin Heckel, Frank Hilberg, Thorsten Lehmann-Lintz, Guenter Linz, Joerg Kley, Jacobus Van Meel, Werner Rall, Gerald Roth, Peter Sieger, Ulrike Tontsch-Grunt
  • Publication number: 20060154939
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 20, 2005
    Publication date: July 13, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Park, Nveed Chaudhary, Thorsten Lehmann-Lintz, Armin Heckel, Gerald Roth, Joerg Kley, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Publication number: 20060148883
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 20, 2005
    Publication date: July 6, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Park, Nveed Chaudhary, Gerald Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley
  • Publication number: 20060142373
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 20, 2005
    Publication date: June 29, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Park, Gerald Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Publication number: 20060135592
    Abstract: The invention relates to indolinone compounds of formula (I), wherein Y and R1 to R8 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.
    Type: Application
    Filed: December 16, 2005
    Publication date: June 22, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Steffen Steurer, Ralph Brueckner, Bernd Krist, Bodo Betzemeier, Frank Hilberg, Armin Heckel, Gerald Roth, Joerg Kley, Thorsten Lehmann-Lintz
  • Publication number: 20050267120
    Abstract: Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Application
    Filed: April 13, 2005
    Publication date: December 1, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20050267115
    Abstract: Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Application
    Filed: April 13, 2005
    Publication date: December 1, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20050267093
    Abstract: Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R1, R2, and R3 have the meanings given in claim 1, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.
    Type: Application
    Filed: December 23, 2004
    Publication date: December 1, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Ralf Lotz, Philipp Lustenberger, Stephan Mueller, Gerald Roth, Klaus Rudolf, Marcus Schindler, Dirk Stenkamp, Leo Thomas
  • Publication number: 20050245500
    Abstract: Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.
    Type: Application
    Filed: March 3, 2005
    Publication date: November 3, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Gerald Roth, Philipp Lustenberger, Dirk Stenkamp, Stephan Mueller, Thorsten Lehmann-Lintz, Marcus Schindler, Leo Thomas, Ralf Lotz, Marco Santagostino
  • Publication number: 20050245529
    Abstract: Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Application
    Filed: April 13, 2005
    Publication date: November 3, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20050239826
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Application
    Filed: April 13, 2005
    Publication date: October 27, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20050234120
    Abstract: The present invention relates to aryl-containing 5-acylindolinones of general formula wherein R1 to R3 are defined herein, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on protein kinases, particularly an inhibiting effect on the activity of glycogen synthase kinase (GSK-3).
    Type: Application
    Filed: March 10, 2005
    Publication date: October 20, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Gerald Roth, Joerg Kley, Stefan Hoerer, Ingo Uphues
  • Publication number: 20050234101
    Abstract: Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Application
    Filed: April 13, 2005
    Publication date: October 20, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Publication number: 20050209302
    Abstract: The present invention relates to alkyl-containing 5-acylindolinones of general formula wherein R1 to R3 are defined herein, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on protein kinases, particularly an inhibiting effect on the activity of glycogen synthase kinase (GSK-3).
    Type: Application
    Filed: March 10, 2005
    Publication date: September 22, 2005
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Armin Heckel, Gerald Roth, Joerg Kley, Stefan Hoerer, Ingo Uphues